Hostname: page-component-8448b6f56d-tj2md Total loading time: 0 Render date: 2024-04-24T16:21:47.870Z Has data issue: false hasContentIssue false

A single-blind, randomised controlled trial on the effects of lithium and quetiapine monotherapy on the trajectory of cognitive functioning in first episode mania: A 12-month follow-up study

Published online by Cambridge University Press:  23 March 2020

R. Daglas*
Affiliation:
Orygen, The National Centre of Excellence in Youth Mental Health, Locked Bag 10 (35, Poplar Road), Parkville Victoria, 3052, Australia Centre for Youth Mental Health, University of Melbourne, 35 Poplar Road, Parkville Victoria, 3052, Australia
S.M. Cotton
Affiliation:
Orygen, The National Centre of Excellence in Youth Mental Health, Locked Bag 10 (35, Poplar Road), Parkville Victoria, 3052, Australia Centre for Youth Mental Health, University of Melbourne, 35 Poplar Road, Parkville Victoria, 3052, Australia
K. Allott
Affiliation:
Orygen, The National Centre of Excellence in Youth Mental Health, Locked Bag 10 (35, Poplar Road), Parkville Victoria, 3052, Australia Centre for Youth Mental Health, University of Melbourne, 35 Poplar Road, Parkville Victoria, 3052, Australia
M. Yücel
Affiliation:
Melbourne Neuropsychiatry Centre, Department of Psychiatry, University of Melbourne and Melbourne Health161, Barry Street, Carlton South Victoria, 3053, Australia Brain and Mental Health Laboratory (BMH), School of Psychological Sciences & Monash Biomedical Imaging Facility, Monash University, Clayton, Australia
C.A. Macneil
Affiliation:
Orygen Youth Health-Clinical Program35, Poplar Road Parkville, 3052, Australia
M.K. Hasty
Affiliation:
Orygen Youth Health-Clinical Program35, Poplar Road Parkville, 3052, Australia
B. Murphy
Affiliation:
Department of Psychiatry, Monash University, Clayton, Australia
C. Pantelis
Affiliation:
Melbourne Neuropsychiatry Centre, Department of Psychiatry, University of Melbourne and Melbourne Health161, Barry Street, Carlton South Victoria, 3053, Australia Florey Institute for Neuroscience and Mental Health, Kenneth Myer Building, Royal Parade, Parkville, Australia
K.T. Hallam
Affiliation:
Department of Psychology, Victoria University, Melbourne, Australia
L.P. Henry
Affiliation:
Orygen, The National Centre of Excellence in Youth Mental Health, Locked Bag 10 (35, Poplar Road), Parkville Victoria, 3052, Australia
P. Conus
Affiliation:
Treatment and Early Intervention in Psychosis Program (TIPP), département de psychiatrie CHUV, université de Lausanne, clinique de Cery, Prilly, Switzerland
A. Ratheesh
Affiliation:
Orygen, The National Centre of Excellence in Youth Mental Health, Locked Bag 10 (35, Poplar Road), Parkville Victoria, 3052, Australia Centre for Youth Mental Health, University of Melbourne, 35 Poplar Road, Parkville Victoria, 3052, Australia Orygen Youth Health-Clinical Program35, Poplar Road Parkville, 3052, Australia
L. Kader
Affiliation:
Orygen Youth Health-Clinical Program35, Poplar Road Parkville, 3052, Australia
M.T.H. Wong
Affiliation:
School of Psychology and Psychiatry, Faculty of Medicine,Nursing and Health Sciences, Monash University, Clayton, Australia
P.D. McGorry
Affiliation:
Orygen, The National Centre of Excellence in Youth Mental Health, Locked Bag 10 (35, Poplar Road), Parkville Victoria, 3052, Australia Centre for Youth Mental Health, University of Melbourne, 35 Poplar Road, Parkville Victoria, 3052, Australia Orygen Youth Health-Clinical Program35, Poplar Road Parkville, 3052, Australia
M. Berk
Affiliation:
Orygen, The National Centre of Excellence in Youth Mental Health, Locked Bag 10 (35, Poplar Road), Parkville Victoria, 3052, Australia Centre for Youth Mental Health, University of Melbourne, 35 Poplar Road, Parkville Victoria, 3052, Australia Florey Institute for Neuroscience and Mental Health, Kenneth Myer Building, Royal Parade, Parkville, Australia IMPACT Strategic Research Centre, School of Medicine, Deakin University, PO Box 281 Geelong, 3220, Australia Barwon Health and the Geelong Clinic, Swanston Centre, PO Box 281, Geelong Victoria, 3220, Australia
*
*Corresponding author.Orygen, The National Centre of Excellence in Youth Mental Health, Locked Bag 10 (35, Poplar Road), Parkville, 3052 Victoria, Australia. Tel.: +613 9342 2994; fax: +613 9342 2858. E-mail address:rose.daglas@orygen.org.au (R. Daglas).
Get access

Abstract

Background

Cognitive deficits have been reported during the early stages of bipolar disorder; however, the role of medication on such deficits remains unclear. The aim of this study was to compare the effects of lithium and quetiapine monotherapy on cognitive performance in people following first episode mania.

Methods

The design was a single-blind, randomised controlled trial on a cohort of 61 participants following first episode mania. Participants received either lithium or quetiapine monotherapy as maintenance treatment over a 12-month follow-up period. The groups were compared on performance outcomes using an extensive cognitive assessment battery conducted at baseline, month 3 and month 12 follow-up time-points.

Results

There was a significant interaction between group and time in phonemic fluency at the 3-month and 12-month endpoints, reflecting greater improvements in performance in lithium-treated participants relative to quetiapine-treated participants. After controlling for multiple comparisons, there were no other significant interactions between group and time for other measures of cognition.

Conclusion

Although the effects of lithium and quetiapine treatment were similar for most cognitive domains, the findings imply that early initiation of lithium treatment may benefit the trajectory of cognition, specifically verbal fluency in young people with bipolar disorder. Given that cognition is a major symptomatic domain of bipolar disorder and has substantive effects on general functioning, the ability to influence the trajectory of cognitive change is of considerable clinical importance.

Type
Original article
Copyright
Copyright © European Psychiatric Association 2015

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Alda, MLithium in the treatment of bipolar disorder: pharmacology and pharmacogenetics. Mol Psychiatry 2015;20(6):661670 [Epub 2015/02/18]CrossRefGoogle ScholarPubMed
Allin, MP, Marshall, N, Schulze, K, Walshe, M, Hall, MH, Picchioni, M, et al.A functional MRI study of verbal fluency in adults with bipolar disorder and their unaffected relatives. Psychol Med 2010;40(12):20252035 [Epub 2010/02/12]CrossRefGoogle ScholarPubMed
APA, Practice guidelines for the treatment of patients with bipolar disorder. Am J Psychiatry 2002;159(4 Suppl.):150.Google Scholar
Atmaca, M, Yildirim, H, Ozdemir, H, Ogur, E, Tezcan, EHippocampal 1H MRS in patients with bipolar disorder taking valproate versus valproate plus quetiapine. Psychol Med 2007;37(1):121129 [Epub 2006/11/11]CrossRefGoogle ScholarPubMed
Bearden, CE, Glahn, DC, Caetano, S, Olvera, RL, Fonseca, M, Najt, P, et al.Evidence for disruption in prefrontal cortical functions in juvenile bipolar disorder. Bipolar Disord 2007;9(Suppl. 1):145159 [Epub 2007/11/22]CrossRefGoogle ScholarPubMed
Berger, GE, Wood, SJ, Ross, M, Hamer, CA, Wellard, RM, Pell, G, et al.Neuroprotective effects of low-dose lithium in individuals at ultra-high risk for psychosis. A longitudinal MRI/MRS study. Curr Pharm Des 2012;18(4):570575 [Epub 2012/01/14]CrossRefGoogle ScholarPubMed
Berk, M, Kapczinski, F, Andreazza, AC, Dean, OM, Giorlando, F, Maes, M, et al.Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev 2011;35(3):804817 [Epub 2010/10/12]CrossRefGoogle ScholarPubMed
Bian, Q, Kato, T, Monji, A, Hashioka, S, Mizoguchi, Y, Horikawa, H, et al.The effect of atypical antipsychotics, perospirone, ziprasidone and quetiapine on microglial activation induced by interferon-gamma. Prog Neuropsychopharmacol Biol Psychiatry 2008;32(1):4248 [Epub 2007/08/25]CrossRefGoogle ScholarPubMed
Bora, E, Yucel, M, Pantelis, CCognitive endophenotypes of bipolar disorder: a meta-analysis of neuropsychological deficits in euthymic patients and their first-degree relatives. J Affect Disord 2009;113(1–2):120 [Epub 2008/08/08]CrossRefGoogle ScholarPubMed
Bourne, C, Aydemir, O, Balanza-Martinez, V, Bora, E, Brissos, S, Cavanagh, JT, et al.Neuropsychological testing of cognitive impairment in euthymic bipolar disorder: an individual patient data meta-analysis. Acta Psychiatr Scand 2013;128(3):149162 [Epub 2013/04/27]CrossRefGoogle ScholarPubMed
Bowden, CL, Grunze, H, Mullen, J, Brecher, M, Paulsson, B, Jones, M, et al.A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. J Clin Psychiatry 2005;66(1):111121 [Epub 2005/01/27]CrossRefGoogle ScholarPubMed
Calabrese, JR, Keck, PE Jr., Macfadden, W, Minkwitz, M, Ketter, TA, Weisler, RH, et al.A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 2005;162(7):13511360 [Epub 2005/07/05]CrossRefGoogle ScholarPubMed
Daglas, R, Yucel, M, Cotton, S, Allott, K, Hetrick, S, Berk, MCognitive impairment in first episode mania: a systematic review of the evidence. Int J Bipolar Disord 3(9)2015CrossRefGoogle Scholar
Daglas, R, Allott, K, Yucel, M, Henry, LP, Macneil, CA, Hasty, MK, et al.Cognitive functioning following stabilsation from first episode mania. Manuscript submitted for publication 2015.Google Scholar
de Sousa, RT, van de Bilt, MT, Diniz, BS, Ladeira, RB, Portela, LV, Souza, DO, et al.Lithium increases plasma brain-derived neurotrophic factor in acute bipolar mania: a preliminary 4-week study. Neurosci Lett 2011;494(1):5456 [Epub 2011/03/03]CrossRefGoogle ScholarPubMed
Forester, BP, Finn, CT, Berlow, YA, Wardrop, M, Renshaw, PF, Moore, CMBrain lithium, N-acetyl aspartate and myo-inositol levels in older adults with bipolar disorder treated with lithium: a lithium-7 and proton magnetic resonance spectroscopy study. Bipolar Disord 2008;10(6):691700 [Epub 2008/10/08]CrossRefGoogle ScholarPubMed
Geddes, JR, Burgess, S, Hawton, K, Jamison, K, Goodwin, GMLong-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials. Am J Psychiatry 2004;161(2):217222 [Epub 2004/02/03]CrossRefGoogle ScholarPubMed
Ghaemi, SN, Sachs, GS, Chiou, AM, Pandurangi, AK, Goodwin, KIs bipolar disorder still underdiagnosed? Are antidepressants overutilized?. J Affect Disord 1999;52(1–3):135144 [Epub 1999/06/05]CrossRefGoogle ScholarPubMed
Hajek, T, Bauer, M, Pfennig, A, Cullis, J, Ploch, J, O’Donovan, C, et al.Large positive effect of lithium on prefrontal cortex N-acetylaspartate in patients with bipolar disorder: 2-centre study. J Psychiatry Neurosci 2012;37(3):185192 [Epub 2012/02/23]CrossRefGoogle ScholarPubMed
Hallahan, B, Newell, J, Soares, JC, Brambilla, P, Strakowski, SM, Fleck, DE, et al.Structural magnetic resonance imaging in bipolar disorder: an international collaborative mega-analysis of individual adult patient data. Biol Psychiatry 2011;69(4):326335 [Epub 2010/10/30]CrossRefGoogle ScholarPubMed
Hammers, D, Spurgeon, E, Ryan, K, Persad, C, Barbas, N, Heidebrink, J, et al.Validity of a brief computerized cognitive screening test in dementia. J Geriatr Psychiatry Neurol 2012;25(2):8999 [Epub 2012/06/13]CrossRefGoogle ScholarPubMed
Kessing, LV, Vradi, E, Andersen, PKStarting lithium prophylaxis early v. late in bipolar disorder. Br J Psychiatry 2014;205(3):214220 [Epub 2014/07/12]CrossRefGoogle ScholarPubMed
Kozicky, JM, Torres, IJ, Bond, DJ, Lam, RW, Yatham, LNComparison of neuropsychological effects of adjunctive risperidone or quetiapine in euthymic patients with bipolar I disorder. Int Clin Psychopharmacol 2012;27(2):9199 [Epub 2011/11/30]CrossRefGoogle ScholarPubMed
Lebowitz, BK, Shear, PK, Steed, MA, Strakowski, SMVerbal fluency in mania: relationship to number of manic episodes. Neuropsychiatry Neuropsychol Behav Neurol 2001;14(3):177182.Google ScholarPubMed
Lee, RS, Hermens, DF, Scott, J, Redoblado-Hodge, MA, Naismith, SL, Lagopoulos, J, et al.A meta-analysis of neuropsychological functioning in first-episode bipolar disorders. J Psychiatr Res 2014;57C:111 [Epub 2014/07/14]CrossRefGoogle Scholar
Levine, AJ, Miller, EN, Becker, JT, Selnes, OA, Cohen, BANormative data for determining significance of test-retest differences on eight common neuropsychological instruments. Clin Neuropsychol 2004;18(3):373384 [Epub 2005/03/03]CrossRefGoogle ScholarPubMed
Lezak, MDNeuropsychological assessment Fourth ed.Oxford University Press; 2004.Google Scholar
Lopez-Jaramillo, C, Lopera-Vasquez, J, Ospina-Duque, J, Garcia, J, Gallo, A, Cortez, V, et al.Lithium treatment effects on the neuropsychological functioning of patients with bipolar I disorder. J Clin Psychiatry 2010;71(8):10551060 [Epub 2010/04/07]CrossRefGoogle ScholarPubMed
Miura, T, Noma, H, Furukawa, TA, Mitsuyasu, H, Tanaka, S, Stockton, S, et al.Comparative efficacy and tolerability of pharmacological treatments in the maintenance treatment of bipolar disorder: a systematic review and network meta-analysis. Lancet Psychiatry 2014;1(5):351359 [Epub 2015/09/12]CrossRefGoogle ScholarPubMed
Muralidharan, K, Kozicky, JM, Bucker, J, Silveira, LE, Torres, IJ, Yatham, LNAre cognitive deficits similar in remitted early bipolar I disorder patients treated with lithium or valproate? Data from the STOP-EM study. Eur Neuropsychopharmacol 2015;25(2):223230 [Epub 2014/09/28]CrossRefGoogle ScholarPubMed
Murphy, BP, Pang, TY, Hannan, AJ, Proffitt, TM, McConchie, M, Kerr, M, et al.Vascular endothelial growth factor and brain-derived neurotrophic factor in quetiapine treated first-episode psychosis. Schizophr Res Treat. 2014;2014:719395 [Epub 2014/03/29]Google ScholarPubMed
Purdon, SE, Malla, A, Labelle, A, Lit, WNeuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol. J Psychiatry Neurosci 2001;26(2):137149 [Epub 2001/04/09]Google ScholarPubMed
Rybakowski, JK, Suwalska, AExcellent lithium responders have normal cognitive functions and plasma BDNF levels. Int J Neuropsychopharmacol 2010;13(5):617622 [Epub 2010/04/16]CrossRefGoogle ScholarPubMed
Rybakowski, JK, Permoda-Osip, A, Borkowska, AResponse to prophylactic lithium in bipolar disorder may be associated with a preservation of executive cognitive functions. Eur Neuropsychopharmacol 2009;19(11):791795 [Epub 2009/07/07]CrossRefGoogle ScholarPubMed
Schimmelmann, BG, Conus, P, Edwards, J, McGorry, PD, Lambert, MDiagnostic stability 18 months after treatment initiation for first-episode psychosis. J Clin Psychiatry 2005;66(10):12391246 [Epub 2005/11/02]CrossRefGoogle ScholarPubMed
Senturk, V, Goker, C, Bilgic, A, Olmez, S, Tugcu, H, Oncu, B, et al.Impaired verbal memory and otherwise spared cognition in remitted bipolar patients on monotherapy with lithium or valproate. Bipolar Disord 2007;9(Suppl. 1):136144 [Epub 2007/11/22]CrossRefGoogle ScholarPubMed
Snyder, PJ, Werth, J, Giordani, B, Caveney, AF, Feltner, D, Maruff, PA method for determining the magnitude of change across different cognitive functions in clinical trials: the effects of acute administration of two different doses alprazolam. Hum Psychopharmacol 2005;20(4):263273 [Epub 2005/05/25]CrossRefGoogle ScholarPubMed
Tabares-Seisdedos, R, Balanza-Martinez, V, Sanchez-Moreno, J, Martinez-Aran, A, Salazar-Fraile, J, Selva-Vera, G, et al.Neurocognitive and clinical predictors of functional outcome in patients with schizophrenia and bipolar I disorder at one-year follow-up. J Affect Disord 2008;109(3):286299 [Epub 2008/02/22]CrossRefGoogle ScholarPubMed
Torrent, C, Martinez-Aran, A, Daban, C, Amann, B, Balanza-Martinez, V, del Mar Bonnin, C, et al.Effects of atypical antipsychotics on neurocognition in euthymic bipolar patients. Compr Psychiatry 2011;52(6):613622 [Epub 2011/02/08]CrossRefGoogle ScholarPubMed
Wingo, AP, Wingo, TS, Harvey, PD, Baldessarini, RJEffects of lithium on cognitive performance: a meta-analysis. J Clin Psychiatry 2009;70(11):15881597 [Epub 2009/08/20]CrossRefGoogle ScholarPubMed
Xu, H, Chen, Z, He, J, Haimanot, S, Li, X, Dyck, L, et al.Synergetic effects of quetiapine and venlafaxine in preventing the chronic restraint stress-induced decrease in cell proliferation and BDNF expression in rat hippocampus. Hippocampus 2006;16(6):551559 [Epub 2006/05/03]CrossRefGoogle ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.